Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection

Toll-like receptor 3 (TLR3) plays a key role in innate immunity by recognizing pathogenic, double-stranded RNAs. Thus, activation of TLR3 is a major factor in antiviral defense and tumor eradication. Although downregulation of TLR3 gene expression has been mainly reported in patients infected with hepatitis C virus (HCV), the influence of TLR3 genotype on the risk of HCV infection, HCV-related cirrhosis, and/or hepatocellular carcinoma (HCC) remains to be determined. Single-nucleotide polymorphisms (SNPs) within the TLR3 gene and their associations with HCV-related disease risk were investigated in a Saudi Arabian population in this study. Eight TLR3 SNPs were analyzed in 563 patients with HCV, which consisted of 437 patients with chronic HCV infections, 88 with HCV-induced liver cirrhosis, and 38 with HCC. A total of 599 healthy control subjects were recruited to the study. Among the eight TLR3 SNPs studied, the rs78726532 SNP was strongly associated with HCV infection when compared to that in healthy control subjects. The rs5743314 was also strongly associated with HCV-related liver disease progression (cirrhosis and HCC). In summary, these results indicate that distinct genetic variants of TLR3 SNPs are associated with HCV infection and HCV-mediated liver disease progression in the Saudi Arabian population.

[1]  J. Wang,et al.  Expression of toll-like receptors in hepatic cirrhosis and hepatocellular carcinoma. , 2016, Genetics and molecular research : GMR.

[2]  Xian-Tao Zeng,et al.  Toll-Like Receptor 3 is Associated With the Risk of HCV Infection and HBV-Related Diseases , 2016, Medicine.

[3]  Shan Li,et al.  Genetic polymorphisms in Toll-like receptor 3 gene are associated with the risk of hepatitis B virus-related liver diseases in a Chinese population. , 2015, Gene.

[4]  J. Qin,et al.  TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis , 2015, BMC Cancer.

[5]  S. Demachki,et al.  Toll-like receptor 3 gene polymorphisms are not associated with the risk of hepatitis B and hepatitis C virus infection. , 2015, Revista da Sociedade Brasileira de Medicina Tropical.

[6]  P. Sadhukhan,et al.  Modulation of TLR 3, 7 and 8 Expressions in HCV Genotype 3 Infected Individuals: Potential Correlations of Pathogenesis and Spontaneous Clearance , 2014, BioMed research international.

[7]  Jie Wang,et al.  Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758 , 2014, Archives of Virology.

[8]  L. Canani,et al.  Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus. , 2014, European journal of endocrinology.

[9]  D. Jackson,et al.  TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease , 2014, Front. Immunol..

[10]  Caroline L. Wilson,et al.  Quiescent Hepatic Stellate Cells Functionally Contribute to the Hepatic Innate Immune Response via TLR3 , 2014, PloS one.

[11]  D. D. Des Jarlais,et al.  Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. , 2013, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[12]  L. Rinaldi,et al.  Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. , 2013, World journal of hepatology.

[13]  Li Chen,et al.  Inhibitory effect of dsRNA TLR3 agonist in a rat hepatocellular carcinoma model. , 2013, Molecular medicine reports.

[14]  A. G. Romaschenko,et al.  Association of single nucleotide polymorphism rs3775291 in the coding region of the TLR3 gene with predisposition to tick-borne encephalitis in a Russian population. , 2013, Antiviral research.

[15]  H. Keyvani,et al.  Hepatitis C virus--proteins, diagnosis, treatment and new approaches for vaccine development. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[16]  Ruth R. Montgomery,et al.  Impaired Toll-Like Receptor 3-Mediated Immune Responses from Macrophages of Patients Chronically Infected with Hepatitis C Virus , 2012, Clinical and Vaccine Immunology.

[17]  C. Hodgkinson,et al.  Send Orders of Reprints at Reprints@benthamscience.org Toll-like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms , 2022 .

[18]  Nisha A. Viswan,et al.  Toll‐like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients , 2012, Journal of medical virology.

[19]  L. Padyukov,et al.  Polymorphisms in Toll-like receptor 3 confer natural resistance to human herpes simplex virus type 2 infection. , 2012, The Journal of general virology.

[20]  M. Clerici,et al.  A Common Polymorphism in TLR3 Confers Natural Resistance to HIV-1 Infection , 2012, The Journal of Immunology.

[21]  Song He,et al.  Double-stranded RNA-induced TLR3 activation inhibits angiogenesis and triggers apoptosis of human hepatocellular carcinoma cells. , 2011, Oncology reports.

[22]  W. Tak,et al.  Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis , 2011, The Korean journal of hepatology.

[23]  M. Asim,et al.  Promoter region polymorphism & expression profile of toll like receptor-3 (TLR-3) gene in chronic hepatitis C virus (HCV) patients from India , 2011, The Indian journal of medical research.

[24]  A. Nahum,et al.  The L412F variant of Toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity. , 2011, The Journal of allergy and clinical immunology.

[25]  B. Gao,et al.  Toll-Like Receptor 3 in Liver Diseases , 2010, Gastroenterology research and practice.

[26]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[27]  William M. Lee,et al.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.

[28]  M. Tinguely,et al.  Plasma cell toll‐like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production , 2009, Immunology.

[29]  Yuqiong Liang,et al.  Toll-Like Receptor 3 Mediates Establishment of an Antiviral State against Hepatitis C Virus in Hepatoma Cells , 2009, Journal of Virology.

[30]  G. Ramadori,et al.  TLR3 gene polymorphisms and liver disease manifestations in chronic hepatitis C , 2009, Journal of medical virology.

[31]  D. Lavanchy,et al.  The global burden of hepatitis C , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[32]  H. Saya,et al.  p53 Regulates Toll-Like Receptor 3 Expression and Function in Human Epithelial Cell Lines , 2008, Molecular and Cellular Biology.

[33]  P. Halfon,et al.  FibroTest-ActiTest as a non-invasive marker of liver fibrosis. , 2008, Gastroenterologie clinique et biologique.

[34]  N. Hotta,et al.  Expression of Toll‐like receptors in chronic hepatitis C virus infection , 2007, Journal of gastroenterology and hepatology.

[35]  C. Graham,et al.  Differential expression of toll‐like receptor mRNA in treatment non‐responders and sustained virologic responders at baseline in patients with chronic hepatitis C , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[36]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[37]  Z. Tian,et al.  TLR3 ligand-induced accumulation of activated splenic natural killer cells into liver. , 2005, Cellular & molecular immunology.

[38]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[39]  V. de Lédinghen,et al.  Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study , 2005, Gut.

[40]  Masahiro Ito,et al.  Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis , 2005, Laboratory Investigation.

[41]  T. Seya,et al.  Toll‐Like Receptor 3: A Link between Toll‐Like Receptor, Interferon and Viruses , 2004, Microbiology and immunology.

[42]  P. Godowski,et al.  Tissue Expression of Human Toll-Like Receptors and Differential Regulation of Toll-Like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines , 2002, The Journal of Immunology.

[43]  P. Allavena,et al.  Differential Expression and Regulation of Toll-Like Receptors (TLR) in Human Leukocytes: Selective Expression of TLR3 in Dendritic Cells1 , 2000, The Journal of Immunology.

[44]  A. Muir.  The natural history of hepatitis C viral infection. , 2000, Seminars in gastrointestinal disease.

[45]  F. Ali-Eldin,et al.  Expression of Toll like receptors 3 & 7 in peripheral blood from patients with chronic hepatitis C virus infection and their correlation with interferon-alpha. , 2013, The Egyptian journal of immunology.

[46]  M. Ajuebor,et al.  Toll-Like Receptor 3 Ligand Dampens Liver Inflammation by Stimulating V (cid:1) 14 Invariant Natural Killer T Cells to Negatively Regulate (cid:2)(cid:3) T Cells , 2010 .